

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 10,400,025 B2
APPLICATION NO. : 15/879294
DATED : September 3, 2019
INVENTOR(S) : Eric Furfine et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

In Claim 3, please replace “amino acids 27-475 of SEQ ID NO:4” with --amino acids 27-457 of SEQ ID NO:4--.

In Claim 8, please replace “amino acids 27-475 of SEQ ID NO:4” with --amino acids 27-457 of SEQ ID NO:4--.

In Claim 11, please replace “amino acids 27-475 of SEQ ID NO:4” with --amino acids 27-457 of SEQ ID NO:4--.

Signed and Sealed this
Twenty-first Day of December, 2021



Drew Hirshfeld
*Performing the Functions and Duties of the
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office*

Electronically Filed 10/27/2021		
PETITION FOR CERTIFICATE OF CORRECTION Address to: Mail Stop Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	REGN-024CON7
	First Named Inventor	Eric Furfine
	Patent Number	10,400,025
	Issue Date	September 3, 2019
	Application Number	15/879,294
	Filing Date	January 24, 2018
	Title:	<i>“VEGF Antagonist Formulations Suitable for Intravitreal Administration”</i>

Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent.

Please correct the typographical errors in claims 3, 8 and 11 from “amino acids 27-475 of SEQ ID NO:4” to read –amino acids 27-457 of SEQ ID NO:4--. Support for this amendment can be found at column 6, line 25 of the issued patent.

The fee of \$160.00 pursuant to 37 C.F.R. § 1.20(a) is included herewith. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number REGN-024CON7.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 27, 2021

By: /Karl Bozicevic, Reg. No. 28,807/
Karl Bozicevic
Reg. No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP
201 Redwood Shores Parkway, Suite 200
Redwood City, CA 94065
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 10,400,025
APPLICATION NO. : 15/879,294
ISSUE DATE : September 3, 2019
INVENTOR(S) : Eric Furfine et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In claim 3, please replace "amino acids 27-475 of SEQ ID NO:4" with --amino acids 27-457 of SEQ ID NO:4--.

In claim 8, please replace "amino acids 27-475 of SEQ ID NO:4" with --amino acids 27-457 of SEQ ID NO:4--.

In claim 11, please replace "amino acids 27-475 of SEQ ID NO:4" with --amino acids 27-457 of SEQ ID NO:4--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

BOZICEVIC, FIELD & FRANCIS LLP
201 Redwood Shores Pkwy, Suite 200
Redwood City, California 94065

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/879,294	09/03/2019	10400025	REGN-024CON7	9777

96387 7590 08/14/2019
Regeneron - Bozicevic, Field & Francis
201 REDWOOD SHORES PARKWAY
SUITE 200
REDWOOD CITY, CA 94065

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Eric FURFINE, Concord, MA;
REGENERON PHARMACEUTICALS, INC., Tarrytown, NY;
Daniel DIX, LaGrangeville, NY;
Kenneth GRAHAM, Pleasant Valley, NY;
Kelly FRYE, Mendham, NJ;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

96387 7590 05/01/2019
Regeneron - Bozicevic, Field & Francis
201 REDWOOD SHORES PARKWAY
SUITE 200
REDWOOD CITY, CA 94065

EXAMINER	
LOCKARD, JON MCCLELLAND	
ART UNIT	PAPER NUMBER

1647

DATE MAILED: 05/01/2019

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/879,294	01/24/2018	Eric FURFINE	REGN-024CON7	9777

TITLE OF INVENTION: VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	08/01/2019

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

96387 7590 05/01/2019
Regeneron - Bozicevic, Field & Francis
201 REDWOOD SHORES PARKWAY
SUITE 200
REDWOOD CITY, CA 94065

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/879,294	01/24/2018	Eric FURFINE	REGN-024CON7	9777

TITLE OF INVENTION: VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	08/01/2019

EXAMINER	ART UNIT	CLASS-SUBCLASS
LOCKARD, JON MCCLELLAND	1647	424-134100

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

1 _____

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/879,294	01/24/2018	Eric FURFINE	REGN-024CON7	9777
96387	7590	05/01/2019	EXAMINER	
Regeneron - Bozicevic, Field & Francis 201 REDWOOD SHORES PARKWAY SUITE 200 REDWOOD CITY, CA 94065			LOCKARD, JON MCCLELLAND	
			ART UNIT	PAPER NUMBER
			1647	

DATE MAILED: 05/01/2019

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/879,294	Applicant(s) FURFINE et al.	
	Examiner JON M LOCKARD	Art Unit 1647	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Response filed 08 April 2019.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are See Continuation Sheet. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov**.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a) ☐ All b) ☐ Some *c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file areply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892) 2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____. 3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____. 4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____.	5. ☐ Examiner's Amendment/Comment 6. ☐ Examiner's Statement of Reasons for Allowance 7. ☐ Other _____.
---	---

/J.L/ Examiner, Art Unit 1647	/CHRISTINE J SAUD/ Primary Examiner, Art Unit 1647
----------------------------------	---

Continuation of 3. The allowed claim(s) is/are: 12-26 (renumbered as claims 1-15, respectively)

Electronically filed 4/8/2019		
AMENDMENT UNDER 37 C.F.R. §1.111 Address to: Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	REGN-024CON7
	Confirmation No.	9777
	First Named Inventor	Daniel Dix
	Application Number	15/879,294
	Filing Date	January 24, 2018
	Group Art Unit	1647
	Examiner Name	Jon McClelland Lockard
	Title: <i>“VEGF Antagonist Formulations Suitable for Intravitreal Administration”</i>	

Sir:

This amendment is responsive to the Office Action dated January 10, 2019, for which a three-month period for response was given, making this response due on April 10, 2019.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

Amendments to the Specification begin on page 2 of this paper.

Listing of the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 6 of this paper.

AMENDMENTS TO THE SPECIFICATION

Please replace [0001] paragraph beginning on page 1 with the following rewritten paragraph:

[0001] This application is a **continuation of U.S. patent application Ser. No. 15/095,606, filed Apr. 11, 2016, which issued as U.S. Pat. No. 9,914,763 on Mar. 13, 2018, which is a** continuation application of U.S. patent application Ser. No. 14/330,096, filed July 14, 2014, **which issued as U.S. Pat. No. 9,340,594 on May 17, 2016,** which is a continuation of U.S. patent application Ser. No. 13/914,996, filed Jun. 11, 2013, which issued as U.S. Pat. No. 8,802,107 on Aug. 12, 2014, which is a continuation application of U.S. patent application Ser. No. 13/329,770, filed Dec. 19, 2011, which issued as U.S. Pat. No. 8,481,046 on Jul. 9, 2013, which is a continuation application of U.S. patent application Ser. No. 12/883,417, filed Jul. 9, 2010, which issued as U.S. Pat. No. 8,092,803 on Jan. 10, 2012, which is a continuation application of U.S. patent application Ser. No. 12/560,885, filed Sep. 16, 2009, which issued as U.S. Pat. No. 7,807,164 on October 5, 2010, which is a divisional application of U.S. patent application Ser. No. 11/818,463, filed Jun. 14, 2007, which issued as U.S. Pat. No. 7,608,261 on Oct. 27, 2009, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 60/814,484, filed 16 Jun. 2006, which applications are each hereby incorporated by reference.

LISTING OF THE CLAIMS

1. – 11. (Canceled)

12. (Previously Presented) A formulation suitable for intravitreal administration comprising:
- (a) 1 mg/mL to 100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist;
 - (b) an organic co-solvent;
 - (c) 5 mM to 40 mM of a phosphate buffer; and
 - (d) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;

wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

13. (Previously Presented) The formulation of claim 12, wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.

14. (Previously Presented) The formulation of claim 13, wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.

15. (Previously Presented) The formulation of claim 14, wherein the VEGF antagonist is a dimer of the fusion protein.

16. (Previously Presented) The formulation of claim 12, wherein the organic co-solvent is polysorbate 20.

17. (Previously Presented) The formulation of claim 12, wherein the phosphate buffer is sodium phosphate buffer.

18. (Previously Presented) The formulation of claim 12, wherein the stabilizing agent is sucrose.
19. (Previously Presented) A formulation suitable for intravitreal administration comprising:
- (a) 40 mg/mL of a fusion protein comprising amino acids 27-475 of SEQ ID NO:4;
 - (b) 0.03% polysorbate 20;
 - (c) 10 mM sodium phosphate buffer, pH 6.2; and
 - (d) 5% sucrose.
20. (Previously Presented) A method of maintaining stability of a formulation, comprising the steps of:
- (a) adding a vascular endothelial growth factor (VEGF) antagonist to a solution at a concentration of from 1 mg/ml to 100 mg/ml, wherein the solution comprises:
 - (i) an organic co-solvent;
 - (ii) 5 mM to 40 mM of a phosphate buffer; and
 - (iii) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component; and
 - (b) maintaining the formulation over a period of time of from 1 month to 24 months whereby the formulation remain suitable for intravitreal administration.
21. (Previously Presented) The method of claim 20, wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.
22. (Previously Presented) The method of claim 21, wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.
23. (Previously Presented) The method of claim 22, wherein the VEGF antagonist is a dimer

of the fusion protein.

24. (Previously Presented) The method of claim 20, wherein the organic co-solvent is polysorbate 20.

25. (Previously Presented) The method of claim 20, wherein the phosphate buffer is sodium phosphate buffer.

26. (Previously Presented) The method of claim 20, wherein the stabilizing agent is sucrose.

REMARKS

Formal Matters

Claims 12-26 remain pending.

Claims 12-26 were examined and were rejected.

Original claims 1-11 were canceled without prejudice to renewal, without intent to acquiesce to any rejection, and without intent to surrender any subject matter encompassed by the canceled claims. Applicants expressly reserve the right to pursue any canceled subject matter in one or more continuation and/or divisional applications.

No new matter has been added.

Statement under 37 C.F.R. §§1.56 and 1.2

Applicants hereby advise the Examiner of the status of a co-pending application in compliance with the Applicant's duty to disclose under 37 C.F.R. §§1.56 and 1.2 (see also MPEP §2001.06(b)) as discussed in *McKesson Info. Soln. Inc., v. Bridge Medical Inc.*, 487 F.3d 897; 82 USPQ2d 1865 (Fed. Cir. 2007).

Applicants wish to bring to the Examiner's attention co-pending U.S. Patent Application No. 16/159,269, filed October 12, 2018. No actions have been mailed to date.

Applicants wish to bring to the Examiner's attention U.S. Patent Nos. 7,608,261; 8,092,803; 8,481,046; 8,802,107; 9,340,594; 9,914,763; 9,580,489; and 7,807,164 which are all issued patents to which the above-referenced patent application claims priority.

These documents are available on PAIR, and thus are not provided with this communication.

Nonstatutory double patenting

Claims 12-26 were rejected on the ground of nonstatutory obviousness-type double patenting as allegedly unpatentable over claims 1-7 and 11-17 of U.S. Patent No. 8,092,803.

Claims 12-26 were rejected on the ground of nonstatutory obviousness-type double patenting as allegedly unpatentable over claims 1-15 and 17 of U.S. Patent No. 7,608,261

Claims 12-26 were rejected on the ground of nonstatutory obviousness-type double patenting as allegedly unpatentable over claims 1-12 of U.S. Patent No. 9,340,594.

Applicants enclose herewith a terminal disclaimer, disclaiming patent term beyond the expiration date of U.S. Patent Nos. 7,608,261; 8,092,803; 8,481,046; 8,802,107; 9,340,594; 9,914,763; 9,580,489;

and 7,807,164 and U.S. Patent Application Serial No. 16/159,269. Thus, this rejection of claims 12-26 may be withdrawn.

CONCLUSION

Applicants submit that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-024CON7.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 8 April 2019

By: /Karl Bozicevic, Reg. No. 28,807/
Karl Bozicevic
Reg. No. 28,807

Encl. Terminal Disclaimer (2)

BOZICEVIC, FIELD & FRANCIS LLP
201 Redwood Shores Parkway, Suite 200
Redwood City, CA 94065
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/879,294	01/24/2018	Eric FURFINE	REGN-024CON7	9777
96387	7590	01/10/2019	EXAMINER	
Regeneron - Bozicevic, Field & Francis 201 REDWOOD SHORES PARKWAY SUITE 200 REDWOOD CITY, CA 94065			LOCKARD, JON MCCLELLAND	
			ART UNIT	PAPER NUMBER
			1647	
			NOTIFICATION DATE	DELIVERY MODE
			01/10/2019	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docket@bozpat.com

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions.

Status of Application, Amendments, and/or Claims

2. The preliminary amendment filed 24 January 2018 has been received and entered in full. Claims 1-11 have been cancelled, and claims 12-26 have been added. Therefore, claims 12-26 are pending and the subject of this Office Action.

Information Disclosure Statement

3. The information disclosure statements (IDS) submitted on 22 May 2018 and 12 October 2018 have been considered by the examiner.

Specification

4. The disclosure is objected to because of the following informalities:
5. An updated status of the parent nonprovisional applications should be included in the first sentence of the specification.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim

is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

7. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

8. The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit <http://www.uspto.gov/forms/>. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to <http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp>.

9. Claims 12-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 and 11-17 of U.S. Patent No. 8,092,803. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of the ophthalmic formulation of the VEGF antagonist recited in the instant claims is overlapping in scope with the ophthalmic formulation of VEGF antagonist recited in claims 1-7 and 11-17 of U.S. Patent No. 8,092,803. Therefore, the claims are overlapping in scope.

10. Claims 12-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-15 and 17 of U.S. Patent No. 7,608,261. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of the ophthalmic formulation of the VEGF antagonist recited in the instant claims is

overlapping in scope with the ophthalmic formulation of VEGF antagonist recited in claims 1-15 and 17 of U.S. Patent No. 7,608,261. Therefore, the claims are overlapping in scope.

11. Claims 12-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 9,340,594. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of the ophthalmic formulation of the VEGF antagonist recited in the instant claims is overlapping in scope with the ophthalmic formulation of VEGF antagonist recited in claims 1-11 of U.S. Patent No. 9,340,594. Therefore, the claims are overlapping in scope.

12. Claims 12-26 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 9,914,763. Although the conflicting claims are not identical, they are not patentably distinct from each other because the scope of the ophthalmic formulation of the VEGF antagonist recited in the instant claims is overlapping in scope with the ophthalmic formulation of VEGF antagonist recited in claims 1-12 of U.S. Patent No. 9,914,763. Therefore, the claims are overlapping in scope.

Summary

13. No claim is allowed.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon M. Lockard whose telephone number is (571) 272-2717. The examiner can normally be reached on Monday through Friday, 8:00 AM to 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joanne Hama, can be reached on (571) 272-2911. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at **866-217-9197** (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JON M LOCKARD/
Examiner, Art Unit 1647
January 5, 2019

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	15/879,294	
			Filing Date	2018-01-24	
			First Named Inventor	Daniel Dix	
			Art Unit	1629	
			Examiner Name	Jon McClelland Lockard	
Sheet	1	of	1	Attorney Docket Number	REGN-024CON7

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No.	Patent Number Number-Kind Code (if known)	Issue Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1				
	2				

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*	Cite No.	Publication Number Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1				
	2				

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	1					
	2					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/J.L./	1	ANONYMOUS: "Lucentis in the treatment of neovascular (wet) age-related macular degeneration (AMD)", 1 January 2007, pages 1-54	

Examiner Signature	/JON M LOCKARD/	Date Considered	01/04/2019
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	15/879,294	
			Filing Date	2018-01-24	
			First Named Inventor	Daniel Dix	
			Art Unit	1629	
			Examiner Name	Jon McClelland Lockard	
Sheet	1	of	1	Attorney Docket Number	REGN-024CON7

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No.	Patent Number Number-Kind Code (if known)	Issue Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	6100071	2000-08-08	Davis-Smyth et al.	
	2	6897294	2005-05-24	Davis-Smyth et al.	
	3	7052691	2006-05-30	Sleeman et al.	

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*	Cite No.	Publication Number Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	20050281831	2005-12-22	Davis-Smyth et al.	
	2	20060217311	2006-09-28	Dix et al.	
	3	20080085276	2008-04-10	Wiegand et al.	
	4	20140012227	2014-01-09	Sigg et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	1	WO 97/04801	1997-02-13	Genentech, Inc.		
	2	JP 10273450	1998-10-13	Toagosei Co. Ltd.		
	3	WO 99/62536	1999-12-09	Celtrix Pharmaceuticals, Inc.		
	4	WO 2004/091658	2004-10-28	Genentech, Inc.		
	5	WO 2005/000895	2005-01-06	Regeneron Pharmaceuticals, Inc.		
	6	WO 2005011734	2005-02-10	Regeneron Pharmaceuticals, Inc.		
	7	WO 2005/020972	2005-03-10	Eyetech Pharmaceuticals, Inc.		
	8	WO 2006/047325	2006-05-04	Genentech, Inc.		
	9	WO 2006/088650	2006-08-24	Regeneron Pharmaceuticals, Inc.		
	10	WO 2006/104852	2006-10-05	Regeneron Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	FRASER, Hamis M., et al., "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produced Prolonged, Dose-Related Suppression of Ovarian Function," (2004) J. Clin. Endocrin. & Metabol. 90(2):1114-1122	

Examiner Signature	/JON M LOCKARD/	Date Considered	01/04/2019
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

Inventor Information for 15/879294

/J.L./

Inventor Name	City	State/Country
FURFINE, ERIC	CONCORD	MASSACHUSETTS
DIX, DANIEL	LAGRANGEVILLE	NEW YORK
GRAHAM, KENNETH	PLEASANT VALLEY	NEW YORK
FRYE, KELLY	MENDHAM	NEW JERSEY

[App's Info](#) [Contents](#) [Petition Info](#) [Att'y/Agent Info](#) [Continuity Data](#) [Foreign Data](#) **Inventors** [Applicants](#) [Address](#) [Fees](#) [Post Info](#) [Pre-Grant](#)

Search Another: Application # [Search](#) or Patent # [Search](#) or International Registration # [Search](#)

PCT / / [Search](#) or PG PUBS # [Search](#)

Attorney Docket # [Search](#)

Bar Code # [Search](#)

To Go BACK Use BACK Button on Your BROWSER Tool Bar

Back to [FALM](#) [ASSIGNMENT](#) [QASIS](#) Home page

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	15/879,294
				Filing Date	2018-01-24
				First Named Inventor	Daniel Dix
				Art Unit	1629
				Examiner Name	Jon McClelland Lockard
Sheet	1	of	1	Attorney Docket Number	REGN-024CON7

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No.	Patent Number Number-Kind Code (if known)	Issue Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1				
	2				

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*	Cite No.	Publication Number Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1				
	2				

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No.	Foreign Document Number Country Code-Number-Kind Code (if known)	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	1					
	2					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	ANONYMOUS: "Lucentis in the treatment of neovascular (wet) age-related macular degeneration (AMD)", 1 January 2007, pages 1-54	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	15/879,294	
			Filing Date	2018-01-24	
			First Named Inventor	Daniel Dix	
			Art Unit	1629	
			Examiner Name	Jon McClelland Lockard	
Sheet	1	of	1	Attorney Docket Number	REGN-024CON7

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No.	Patent Number	Issue Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	1	6100071	2000-08-08	Davis-Smyth et al.	
	2	6897294	2005-05-24	Davis-Smyth et al.	
	3	7052691	2006-05-30	Sleeman et al.	

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initial*	Cite No.	Publication Number	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
	1	20050281831	2005-12-22	Davis-Smyth et al.	
	2	20060217311	2006-09-28	Dix et al.	
	3	20080085276	2008-04-10	Wiegand et al.	
	4	20140012227	2014-01-09	Sigg et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initial*	Cite No.	Foreign Document Number	Publication Date YYYY-MM-DD	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code-Number-Kind Code (if known)				
	1	WO 97/04801	1997-02-13	Genentech, Inc.		
	2	JP 10273450	1998-10-13	Toagosei Co. Ltd.		
	3	WO 99/62536	1999-12-09	Celtrix Pharmaceuticals, Inc.		
	4	WO 2004/091658	2004-10-28	Genentech, Inc.		
	5	WO 2005/000895	2005-01-06	Regeneron Pharmaceuticals, Inc.		
	6	WO 2005011734	2005-02-10	Regeneron Pharmaceuticals, Inc.		
	7	WO 2005/020972	2005-03-10	Eyetech Pharmaceuticals, Inc.		
	8	WO 2006/047325	2006-05-04	Genentech, Inc.		
	9	WO 2006/088650	2006-08-24	Regeneron Pharmaceuticals, Inc.		
	10	WO 2006/104852	2006-10-05	Regeneron Pharmaceuticals, Inc.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	FRASER, Hamis M., et al., "Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produced Prolonged, Dose-Related Suppression of Ovarian Function," (2004) J. Clin. Endocrin. & Metabol. 90(2):1114-1122	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Electronically Filed

PRELIMINARY AMENDMENT Under 37 CFR § 1.115 Address to: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket No.	REGN-024CON7
	Confirmation No.	To Be Assigned
	First Named Inventor	Furfine, Eric
	Application Number	To Be Assigned
	Filing Date	Herewith
	Group Art Unit	
	Examiner Name	
	Title:	<i>“VEGF Antagonist Formulations Suitable for Intravitreal Administration”</i>

Sir:

Prior to the examination of the above-referenced application on the merits, please enter the amendments below.

AMENDMENTS TO THE CLAIMS

1. – 11. **(Canceled)**

12. **(New)** A formulation suitable for intravitreal administration comprising:

- (a) 1 mg/mL to 100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist;
- (b) an organic co-solvent;
- (c) 5 mM to 40 mM of a phosphate buffer; and
- (d) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;

wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

13. **(New)** The formulation of claim 12, wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.

14. **(New)** The formulation of claim 13, wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.

15. **(New)** The formulation of claim 14, wherein the VEGF antagonist is a dimer of the fusion protein.

16. **(New)** The formulation of claim 12, wherein the organic co-solvent is polysorbate 20.

17. **(New)** The formulation of claim 12, wherein the phosphate buffer is sodium phosphate buffer.

18. **(New)** The formulation of claim 12, wherein the stabilizing agent is sucrose.

19. **(New)** A formulation suitable for intravitreal administration comprising:
- (a) 40 mg/mL of a fusion protein comprising amino acids 27-475 of SEQ ID NO:4;
 - (b) 0.03% polysorbate 20;
 - (c) 10 mM sodium phosphate buffer, pH 6.2; and
 - (d) 5% sucrose.

20. **(New)** A method of maintaining stability of a formulation, comprising the steps of:
- (a) adding a vascular endothelial growth factor (VEGF) antagonist to a solution at a concentration of from 1 mg/ml to 100 mg/ml, wherein the solution comprises:
 - (i) an organic co-solvent;
 - (ii) 5 mM to 40 mM of a phosphate buffer; and
 - (iii) 1.0% to 10% of a stabilizing agent selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;

wherein the VEGF antagonist is a fusion protein comprising an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component; and

- (b) maintaining the formulation over a period of time of from 1 month to 24 months whereby the formulation remain suitable for intravitreal administration.

21. **(New)** The method of claim 20, wherein the first VEGF receptor is human Flt1, and the second VEGF receptor is selected from the group consisting of human Flk1 and human Flt4.

22. **(New)** The method of claim 21, wherein the fusion protein comprises amino acids 27-475 of SEQ ID NO:4.

23. **(New)** The method of claim 22, wherein the VEGF antagonist is a dimer of the fusion protein.

24. **(New)** The method of claim 20, wherein the organic co-solvent is polysorbate 20.

25. **(New)** The method of claim 20, wherein the phosphate buffer is sodium phosphate buffer.

26. **(New)** The method of claim 20, wherein the stabilizing agent is sucrose.

REMARKS UNDER 37 CFR § 1.115

Formal Matters

Claims 12-26 are pending after entry of the amendments set forth herein.

Claims 1-11 are canceled without prejudice.

New claims 12-26 are added. Support for these amendments is found in the originally filed specification and specifically in the Examples.

No new matter has been added.

CONCLUSION

Applicant(s) submit(s) that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any underpayment of fees up to a strict limit of \$3,000.00 beyond that authorized on the credit card, but not more than \$3,000.00 in additional fees due with any communication for the above referenced patent application, including but not limited to any necessary fees for extensions of time, or credit any overpayment of any amount to Deposit Account No. 50-0815, order number REGN-024CON7.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: 24 January 2018

By: /Karl Bozicevic, Reg. No. 28,807/
Karl Bozicevic
Registration No. 28,807

Bozicevic, Field & Francis LLP
201 Redwood Shores Parkway, Suite 200
Redwood City, California 94065
Telephone: (650) 327-3400
Direct: (650) 833-7735
Facsimile: (650) 327-3231

Electronic Acknowledgement Receipt

EFS ID:	31592157
Application Number:	15879294
International Application Number:	
Confirmation Number:	9777
Title of Invention:	VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
First Named Inventor/Applicant Name:	Eric FURFINE
Customer Number:	96387
Filer:	Karl Bozicevic
Filer Authorized By:	
Attorney Docket Number:	REGN-024CON7
Receipt Date:	24-JAN-2018
Filing Date:	
Time Stamp:	18:49:52
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$ 1720
RAM confirmation Number	012518INTEFSW18505200
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	WebADS.pdf	172267	no	9
			eae3993848b1a24785de5ae81199d6b719bb12d7		
Warnings:					
Information:					
2		REGN-024CON7_2018-01-24_p re_amend.pdf	37644	yes	5
			ddb39921f026282b8d1c8f965a29c17bde894477		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Preliminary Amendment		1	1	
	Claims		2	4	
	Applicant Arguments/Remarks Made in an Amendment		5	5	
Warnings:					
Information:					
3		REGN-024CON7_appln_as_fld. pdf	766509	yes	16
			8daf0d517068c168f5c827e98848eb344ea0df38		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	14	
	Claims		15	15	
	Abstract		16	16	
Warnings:					
Information:					

4	Oath or Declaration filed	REGN-024CON7_declaration.pdf	551390 8a857f03087a869974574de3cf74617f361f334f	no	4
Warnings:					
Information:					
5	Sequence Listing	REGN-024CON7_2018-01-24_seq_list_trans.pdf	27186 ab61a68c126b395cfa729708682eb30fefad7db2	no	1
Warnings:					
Information:					
6	Sequence Listing	REGN-024CON7_seq_list.pdf	181040 4a3a95a26c9d81af7c0116a5a4962deb6916ae54	no	7
Warnings:					
Information:					
7	Fee Worksheet (SB06)	fee-info.pdf	34708 9d5d941b73b29071fd243f667a0619399f564cd5	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1770744		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					